UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status No longer recruiting
Unique ID issued by UMIN UMIN000028490
Receipt No. R000032611
Scientific Title A non-interventional, observational, cross-sectional study to assess the impact of Parkinson's disease on quality of life of Parkinson's disease patients and their caregivers in Japan.
Date of disclosure of the study information 2017/08/14
Last modified on 2017/10/31

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A non-interventional, observational, cross-sectional study to assess the impact of Parkinson's disease on quality of life of Parkinson's disease patients and their caregivers in Japan.
Acronym A cross-sectional study to assess the impact of PD on QOL of PD patients and their caregivers in Japan.
Scientific Title A non-interventional, observational, cross-sectional study to assess the impact of Parkinson's disease on quality of life of Parkinson's disease patients and their caregivers in Japan.
Scientific Title:Acronym A cross-sectional study to assess the impact of PD on QOL of PD patients and their caregivers in Japan.
Region
Japan

Condition
Condition Parkinson's disease
Classification by specialty
Neurology
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 The main purpose of this study is to assess the impact of Parkinson's disease on QOL of PD patients and their caregivers in the Japanese population.
Basic objectives2 Others
Basic objectives -Others To assess the impact of PD severity on QOL of PD patients in the Japanese population
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Not applicable

Assessment
Primary outcomes The primary endpoint is PDQ-8 summary index score, PDQ-8 SI.
The primary indicator of PD severity is off-time period per day.
The secondary indicators of PD severity are original H&Y stage, presence of wearing-off (WOQ-9 score), troublesome dyskinesia period per day, motor symptoms (SE-ADL score) and NMS (NMSQ total score).
Key secondary outcomes The secondary endpoints are as follows:
- EQ-5D-5L index value
- PDQ-carer summary index, PDQ-carer SI

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients, who fulfill the following selection criteria, can be included:
- Adult patients with confirmed diagnosis of idiopathic Parkinson's disease
- Willingness and ability to provide informed consent

Caregivers, who fulfill the following selection criteria, can be included:
- Caregivers who are currently taking care of adult patients with confirmed diagnosis of idiopathic Parkinson's disease
- Willingness and ability to provide informed consent
Key exclusion criteria Information from caregivers of patients who have not provided informed consent will not be included.
Target sample size 2000

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Osamu Mikami
Organization AbbVie GK
Division name Medical Affairs
Zip code
Address 3-5-27, Mita, Minato-ku, Tokyo 108-6302, Japan
TEL 03-4577-1101
Email osamu.mikami@abbvie.com

Public contact
Name of contact person
1st name
Middle name
Last name Miwako Ishido
Organization AbbVie GK
Division name Medical Affairs
Zip code
Address 3-5-27, Mita, Minato-ku, Tokyo 108-6302, Japan
TEL 080-4950-5028
Homepage URL
Email miwako.ishido@abbvie.com

Sponsor
Institute AbbVie GK
Institute
Department

Funding Source
Organization AbbVie GK
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs YES
Study ID_1 11563
Org. issuing International ID_1 AbbVie GK
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 一般社団法人 全国パーキンソン病友の会(Japan Parkinson’s Disease Association)

Other administrative information
Date of disclosure of the study information
2017 Year 08 Month 14 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status No longer recruiting
Date of protocol fixation
2017 Year 06 Month 06 Day
Date of IRB
Anticipated trial start date
2017 Year 08 Month 15 Day
Last follow-up date
2017 Year 10 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information The main purpose of this study is to assess the impact of Parkinson's disease on QOL of PD patients and their caregivers in the Japanese population. We expect increasing motor and NMS is associated with poor QOL among PD patients and their caregivers. The study is exploratory in nature and we assume no pre-specified hypotheses about statistical significance and/or direction of correlations.
The study population will consist of Parkinson's disease (PD) patients who belong to Japan Parkinson's Disease Association (JPDA) and their caregivers. This observational study will be performed in a cross-sectional, non-interventional, single-country format. The study will consist of a data-collection period with duration of 2 months. The questionnaires will be sent by mail to PD patients and their caregivers. Completed questionnaires will be collected anonymously by return mail.

Management information
Registered date
2017 Year 08 Month 02 Day
Last modified on
2017 Year 10 Month 31 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000032611

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.